A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia.

ABSTRACT:

Background

Individuals with schizophrenia smoke at higher rates (58%-88%) than the general population (approximately 22%), and have difficulty quitting. We determined whether the combination of sustained-release (SR) bupropion (BUP) with the transdermal nicotine patch (TNP) was well-tolerated and superior to placebo (PLO)+TNP for smoking cessation in schizophrenia.

Methods

A 10-week, double-blind, placebo-controlled trial of BUP (300 mg/day) in combination with TNP (21 mg/24h) for 58 outpatient smokers with schizophrenia was conducted. Primary outcome measures were continuous smoking abstinence in the last 4 weeks of the trial (Days 43-70) and 7-day point prevalence abstinence at 6 months post-target quit date (TQD) (week 26).

Results

Smokers assigned to the BUP+TNP g

SUBMITTER: George TP 

PROVIDER: S-EPMC2693008 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature